New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators

por Tang, Minhong, Meng, Jianghui, Wang, Jiafu
Publicado 2019

Degradation of MYC by the mutant p53 reactivator drug, COTI-2 in breast cancer cells

por Tang, Minhong, Crown, John, Duffy, Michael J
Publicado 2023

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975

por Tang, Minhong, O’Grady, Shane, Crown, John, Duffy, Michael J.
Publicado 2022

Neuronal entry and high neurotoxicity of botulinum neurotoxin A require its N-terminal binding sub-domain

por Wang, Jiafu, Meng, Jianghui, Nugent, Marc, Tang, Minhong, Dolly, J. Oliver
Publicado 2017

Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

por Duffy, Michael J., Tang, Minhong, Rajaram, Subhasree, O’Grady, Shane, Crown, John
Publicado 2022

Ligand-bound Structures and Site-directed Mutagenesis Identify the Acceptor and Secondary Binding Sites of Streptomyces coelicolor Maltosyltransferase GlgE

por Syson, Karl, Stevenson, Clare E. M., Miah, Farzana, Barclay, J. Elaine, Tang, Minhong, Gorelik, Andrii, Rashid, Abdul M., Lawson, David M., Bornemann, Stephen
Publicado 2016

Structural Insight into How Streptomyces coelicolor Maltosyl Transferase GlgE Binds α-Maltose 1-Phosphate and Forms a Maltosyl-enzyme Intermediate

por Syson, Karl, Stevenson, Clare E. M., Rashid, Abdul M., Saalbach, Gerhard, Tang, Minhong, Tuukkanen, Anne, Svergun, Dmitri I., Withers, Stephen G., Lawson, David M., Bornemann, Stephen
Publicado 2014